Hyderabad-based Bharat Biotech’s Typbar or ‘Typhoid Vaccine’ gets the pre-qualification nod from the World Health Organisation; opening doors to market the vaccine across 126 countries globally.
The World Health Organisation (WHO) on Wednesday announced that at the end of December 2017, it had prequalified the first conjugate vaccine for typhoid, Bharat Biotech’s Typbar-TCV. “Typhoid conjugate vaccines (TCVs),” it says “are innovative products that have longer-lasting immunity than older vaccines, require fewer doses, and can be given to young children through routine childhood immunization programs. The fact that the vaccine has been prequalified by WHO means that it meets acceptable standards of quality, safety and efficacy. This makes the vaccine eligible for procurement by UN agencies, such as UNICEF, and Gavi, the Vaccine Alliance.”
